These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 16139447

  • 1. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women.
    Kwok S, Charlton-Menys V, Pemberton P, McElduff P, Durrington PN.
    Maturitas; 2006 Mar 20; 53(4):439-46. PubMed ID: 16139447
    [Abstract] [Full Text] [Related]

  • 2. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy.
    Kwok S, Selby PL, McElduff P, Laing I, Mackness B, Mackness MI, Prais H, Morgan J, Yates AP, Durrington PN, Sci FM.
    Clin Endocrinol (Oxf); 2004 Dec 20; 61(6):760-7. PubMed ID: 15579192
    [Abstract] [Full Text] [Related]

  • 3. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
    Nugent AG, Leung KC, Sullivan D, Reutens AT, Ho KK.
    Clin Endocrinol (Oxf); 2003 Dec 20; 59(6):690-8. PubMed ID: 14974909
    [Abstract] [Full Text] [Related]

  • 4. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
    Chang TC, Lien YR, Chen M, Cheng SP, Chen RJ, Chow SN.
    Acta Obstet Gynecol Scand; 2004 Jul 20; 83(7):661-6. PubMed ID: 15225192
    [Abstract] [Full Text] [Related]

  • 5. The effects of estrogen therapy and estrogen combined with different androgenic progestins on carbohydrate and lipid metabolism in overweight-obese younger postmenopausal women.
    Demir B, Ozturkoglu E, Solaroglu A, Baskan B, Kandemir O, Karabulut E, Haberal A.
    Gynecol Endocrinol; 2008 Jun 20; 24(6):347-53. PubMed ID: 18584415
    [Abstract] [Full Text] [Related]

  • 6. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
    de Kraker AT, Kenemans P, Smolders RG, Kroeks MV, van der Mooren MJ.
    Eur J Obstet Gynecol Reprod Biol; 2009 Feb 20; 142(2):139-44. PubMed ID: 19095343
    [Abstract] [Full Text] [Related]

  • 7. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B, Guzic-Salobir B, Sebestjen M, Keber I.
    Menopause; 2006 Feb 20; 13(4):643-50. PubMed ID: 16837886
    [Abstract] [Full Text] [Related]

  • 8. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
    Godsland IF, Manassiev NA, Felton CV, Proudler AJ, Crook D, Whitehead MI, Stevenson JC.
    Clin Endocrinol (Oxf); 2004 May 20; 60(5):541-9. PubMed ID: 15104556
    [Abstract] [Full Text] [Related]

  • 9. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
    Hirvonen E, Mälkönen M, Manninen V.
    N Engl J Med; 1981 Mar 05; 304(10):560-3. PubMed ID: 7453723
    [Abstract] [Full Text] [Related]

  • 10. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
    Cieraad D, Conradt C, Jesinger D, Bakowski M.
    Arch Gynecol Obstet; 2006 May 05; 274(2):74-80. PubMed ID: 16491367
    [Abstract] [Full Text] [Related]

  • 11. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy.
    Maffei S, Mercuri A, Prontera C, Zucchelli GC, Vassalle C.
    Climacteric; 2006 Dec 05; 9(6):452-8. PubMed ID: 17085378
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.
    Hellgren M, Conard J, Norris L, Kluft C.
    Maturitas; 2009 Mar 20; 62(3):287-93. PubMed ID: 19268506
    [Abstract] [Full Text] [Related]

  • 13. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women.
    Stevenson JC, Rioux JE, Komer L, Gelfand M.
    Climacteric; 2005 Dec 20; 8(4):352-9. PubMed ID: 16390770
    [Abstract] [Full Text] [Related]

  • 14. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate.
    Campagnoli C, Colombo P, De Aloysio D, Gambacciani M, Grazioli I, Nappi C, Serra GB, Genazzani AR.
    Maturitas; 2002 Apr 25; 41(4):299-311. PubMed ID: 12034517
    [Abstract] [Full Text] [Related]

  • 15. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?
    McKenzie J, Jaap AJ, Gallacher S, Kelly A, Crawford L, Greer IA, Rumley A, Petrie JR, Lowe GD, Paterson K, Sattar N.
    Clin Endocrinol (Oxf); 2003 Dec 25; 59(6):682-9. PubMed ID: 14974908
    [Abstract] [Full Text] [Related]

  • 16. The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes.
    Thunell L, Andersson B, Glassell M, Mattsson LA.
    Maturitas; 2006 Mar 20; 53(4):430-8. PubMed ID: 16198072
    [Abstract] [Full Text] [Related]

  • 17. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
    Grisar J, Travica S, Metka M, Pietschmann P.
    Wien Klin Wochenschr; 1999 Dec 23; 111(24):1035-43. PubMed ID: 10677891
    [Abstract] [Full Text] [Related]

  • 18. Dydrogesterone and norethisterone regulate expression of lipoprotein lipase and hormone-sensitive lipase in human subcutaneous abdominal adipocytes.
    Palin SL, McTernan PG, McGee KC, Sturdee DW, Barnett AH, Kumar S.
    Diabetes Obes Metab; 2007 Jul 23; 9(4):585-90. PubMed ID: 17587400
    [Abstract] [Full Text] [Related]

  • 19. Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens.
    Fernandes EO, Moraes RS, Ferlin EL, Wender MC, Ribeiro JP.
    Pacing Clin Electrophysiol; 2005 Jan 23; 28 Suppl 1():S172-7. PubMed ID: 15683490
    [Abstract] [Full Text] [Related]

  • 20. A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.
    van der Mooren MJ, Demacker PN, Thomas CM, Borm GF, Rolland R.
    Eur J Obstet Gynecol Reprod Biol; 1993 Dec 15; 52(2):117-23. PubMed ID: 8157140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.